{"product_id":"drug-synthesis-book-set-9781119185659","title":"Drug Synthesis Book Set","description":"\u003cb\u003eBook Synopsis\u003c\/b\u003e\u003cbr\u003eThis set presents the authoritative and acclaimed Drug Synthesis books edited by Jie Jack Li and Douglas Johnson:  Contemporary Drug Synthesis,  The Art of Drug Synthesis,  Modern Drug Synthesis, and  Innovative Drug Synthesis.\u003cbr\u003e\u003cbr\u003e\u003cb\u003eTable of Contents\u003c\/b\u003e\u003cbr\u003e\u003cb\u003e\u003ci\u003eContemporary Drug Synthesis\u003c\/i\u003e\u003c\/b\u003e \u003cp\u003ePreface v\u003c\/p\u003e \u003cp\u003eTrade Names and Their Corresponding USANs xi\u003c\/p\u003e \u003cp\u003eAcronyms and Abbreviations xiii\u003c\/p\u003e \u003cp\u003eChapter 1. Antithrombotics: Ticlopidine (Ticlid) and Clopidogrel (Plavix) 1\u003c\/p\u003e \u003cp\u003eChapter 2. Anti-inflammatory Cyclooxygenase-2 Selective Inhibitors: Celecoxib (Celebrex) and Rofecoxib (Vioxx) 11\u003c\/p\u003e \u003cp\u003eChapter 3. H\u003csup\u003e+\u003c\/sup\u003e\/K\u003csup\u003e+\u003c\/sup\u003e -ATPase Inhibitors: Esomeprazole (Nexium) 21\u003c\/p\u003e \u003cp\u003eChapter 4. Protein-tyrosine Kinase Inhibitors: Imatnib (Gleevec) and Gefitinib (Iressa) 29\u003c\/p\u003e \u003cp\u003eChapter 5. Non-sedating Antihistamines 39\u003c\/p\u003e \u003cp\u003eChapter 6. Cosmeceuticals: Istretinoin (Accutane), Tazarotene (Tazorac), Minoxidil (Rogaine), and Finasteride (Propecia) 55\u003c\/p\u003e \u003cp\u003eChapter 7. Antibacterials: Ciprofloxacin (Cipro) and Linezolid (Zyvox) 75\u003c\/p\u003e \u003cp\u003eChapter 8. Atypical Antupsychotics 89\u003c\/p\u003e \u003cp\u003eChapter 9. Atovastatin Calcium (Lipitor) 113\u003c\/p\u003e \u003cp\u003eChapter 10. Antidepressants 125\u003c\/p\u003e \u003cp\u003eChapter 11. Anti-obesity: Orlistat (Xenical) 149\u003c\/p\u003e \u003cp\u003eChapter 12. Triptans for Migrane 161\u003c\/p\u003e \u003cp\u003eChapter 13. PDE 5 Inhibitors for Erectile Dysfunction: Sildenafil (Viagra), Vardenafil (Levitra), and Tadalafil (Cialis) 189\u003c\/p\u003e \u003cp\u003eChapter 14. Antiasthmatics 201\u003c\/p\u003e \u003cp\u003eIndex 214\u003c\/p\u003e \u003cp\u003e\u003ci\u003e\u003cb\u003eThe Art of Drug Synthesis\u003c\/b\u003e\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e1 THE ROLE OF MEDICINAL CHEMISTRY IN DRUG DISCOVERY 1\u003cbr\u003e\u003ci\u003eJohn A. Lowe, III\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e2 PROCESS RESEARCH: HOW MUCH? HOW SOON? 11\u003cbr\u003e\u003ci\u003eNeal G. Anderson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e3 AROMATASE INHIBITORS FOR BREAST CANCER: EXEMESTANE (AROMASIN), ANASTROZOLE (ARIMIDEX), AND LETROZOLE (FEMARA) 31\u003cbr\u003e\u003ci\u003eJie Jack Li\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e4 QUINOLONE ANTIBIOTICS: LEVOFLOXACIN (LEVAQUIN), MOXIFLOXACIN (AVELOX), GEMIFLOXACIN (FACTIVE), AND GARENOXACIN (T-3811) 39\u003cbr\u003e\u003ci\u003eChris Limberakis\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e5 TRIAZOLE ANTIFUNGALS: ITRACONAZOLE (SPORANOX), FLUCONAZOLE (DIFLUCAN), VORICONAZOLE (VFEND), AND FOSFLUCONAZOLE (PRODIF) 71\u003cbr\u003e\u003ci\u003eAndrew S. Bell\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e6 NON-NUCLEOSIDE HIV REVERSE TRANSCRIPTASE INHIBITORS 83\u003cbr\u003e\u003ci\u003eArthur Harms\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e7 NEURAMINIDASE INHIBITORS FOR INFLUENZA: OSELTAMIVIR PHOSPHATE (TAMIFLU) AND ZANAMIVIR (RELENZA) 95\u003cbr\u003e\u003ci\u003eDouglas S. Johnson and Jie Jack Li\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e8 PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR (PPAR) AGONISTS FOR TYPE 2 DIABETES 117\u003cbr\u003e\u003ci\u003eJin Li\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e9 ANGIOTENSIN AT1 ANTAGONISTS FOR HYPERTENSION 129\u003cbr\u003e\u003ci\u003eLarry Yet\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e10 LEADING ACE INHIBITORS FOR HYPERTENSION 143\u003cbr\u003e\u003ci\u003eVictor J. Cee and Edward J. Olhava\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e11 DIHYDROPYRIDINE CALCIUM CHANNEL BLOCKERS FOR HYPERTENSION 159\u003cbr\u003e\u003ci\u003eDaniel P. Christen\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e12 SECOND-GENERATION HMG-CoA REDUCTASE INHIBITORS 169\u003cbr\u003e\u003ci\u003eJeffrey A. Pfefferkorn\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e13 CHOLESTEROL ABSORPTION INHIBITORS: EZETIMIBE (ZETIA) 183\u003cbr\u003e\u003ci\u003eStuart B. Rosenblum\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e14 DUAL SELECTIVE SEROTONIN AND NOREPINEPHRINE REUPTAKE INHIBITORS (SSNRIs) FOR DEPRESSION 199\u003cbr\u003e\u003ci\u003eMarta Pineiro-Nunez\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e15 GABAA RECEPTOR AGONISTS FOR INSOMNIA: ZOLPIDEM (AMBIEN), ZALEPLON (SONATA), ESZOPICLONE (ESTORRA, LUNESTA), AND INDIPLON 215\u003cbr\u003e\u003ci\u003ePeter R. Guzzo\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e16 Alpha2Delta LIGANDS: NEURONTIN (GABAPENTIN) AND LYRICA (PREGABALIN) 225\u003cbr\u003e\u003ci\u003ePo-Wai Yuen\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e17 APPROVED TREATMENTS FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER: AMPHETAMINE (ADDERALL), METHYLPHENIDATE (RITALIN), AND ATOMOXETINE (STRATERRA) 241\u003cbr\u003e\u003ci\u003eDavid L. Gray\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eReferences 257\u003c\/p\u003e \u003cp\u003eIndex 261\u003c\/p\u003e \u003cp\u003e\u003ci\u003e\u003cb\u003eModern Drug Synthesis\u003c\/b\u003e\u003c\/i\u003e\u003c\/p\u003e Preface xi \u003cp\u003eContributors xiii\u003c\/p\u003e \u003cp\u003e\u003cb\u003eI. Infectious Diseases 1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eChapter 1. Raltegravir (Isentress), The First-in-class HIV-1 Integrase Inhibitor 3\u003cbr\u003e\u003ci\u003eJulianne A. Hunt\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eChapter 2. Maraviroc (Selzentry), The First-in-class CCR5 Antagonist for the Treatment of HIV 17\u003cbr\u003e\u003ci\u003eDavid Price\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eChapter 3. Darunavir (Prezista), A HIV-1 Protease Inhibitor for Treatment of Multidrug Resistant HIV 29\u003cbr\u003e\u003ci\u003eArun K. Ghosh and Cuthbert D. Martyr\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eII. Cancer 45\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eChapter 4. Decitabine (Dacogen), A DNA Methyltransferase Inhibitor for Cancer 47\u003cbr\u003e\u003ci\u003eJennifer A. Van Camp\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eChapter 5. Capecitabine (Xeloda), An Oral Chemotherapy Agent 57\u003cbr\u003e\u003ci\u003eR. Jason Herr\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eChapter 6. Sorafenib (Nexavar), A Multi-kinase Inhibitor for Advanced Renal Cell Carcinoma and Unresectable Hepatocellular Carcinoma 73\u003cbr\u003e\u003ci\u003eShuanghua Hu\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eChapter 7. Sunitinib (Sutent), An Angiogenesis Inhibitor 87\u003cbr\u003e\u003ci\u003eMartin Pettersson\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eChapter 8. Bortezomib (Velcade), A First-in-class Proteasome Inhibitor 99\u003cbr\u003e\u003ci\u003eBenjamin S. Greener and David S. Millan\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eChapter 9. Pazopanib (Votrient), A VEGFR Tyrosine Kinase Inhibitor for Cancer 111\u003cbr\u003e\u003ci\u003eJi Zhang and Jie Jack Li\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eIII. Cardiovascular and Metabolic Diseases 123\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eChapter 10. Sitagliptin (Januvia), A Treatment for Type 2 Diabetes 125\u003cbr\u003e\u003ci\u003eScott D. Edmondson, Feng Xu, and Joseph D. Armstrong III\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eChapter 11. Aliskiren (Tekturna), The First-in-class Renin Inhibitor for Hypertension 141\u003cbr\u003e\u003ci\u003eVictor J. Cee\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eChapter 12. Vernakalant (Kynapid), An Investigational Drug for the Treatment of Atrial Fibrillation 159\u003cbr\u003e\u003ci\u003eDavid L. Gray\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eChapter 13. Conivaptan (Vaprisol), Vasopressin V1a and V2 Antagonist for Hyponatremia 175\u003cbr\u003e\u003ci\u003eBrian A. Lanman\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eChapter 14. Rivaroxaban (Xarelto), A Factor Xa Inhibitor for the Treatment of Thrombotic Events 191\u003cbr\u003e\u003ci\u003eJi Zhang and Jason Crawford\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eChapter 15. Endothelin Antagonists for the Treatment of Pulmonary Arterial Hypertension 207\u003cbr\u003e\u003ci\u003eDavid Edmonds\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eIV. Central Nervous System Diseases 225\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eChapter 16. Varenicline (Chantix), An α4β2 Nicotinic Receptor Partial Agonist for Smoking Cessation 227\u003cbr\u003e\u003ci\u003eJotham W. Coe, Frank R. Busch and Robert A. Singer\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eChapter 17. Donepezil, Rivastigmine, Galantamine: Cholinesterase Inhibitors for Alzheimer's Disease 249\u003cbr\u003e\u003ci\u003eSubas Sakya and Kapil Karki\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eChapter 18. Aprepitant (Emend), A NK1 Receptor Antagonist for the Treatment of Post-chemotherapy Emesis 275\u003cbr\u003e\u003ci\u003eJohn A. Lowe, III\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eChapter 19. Armodafinil (Nuvigil), A Psychostimulant for the Treatment of Narcolepsy 291\u003cbr\u003e\u003ci\u003eJi Zhang and Jason Crawford\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003e\u003cb\u003eV. Miscellaneous 307\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eChapter 20. Raloxifene (Evista), A Selective Estrogen Receptor Modulator (SERM) 309\u003cbr\u003e\u003ci\u003eMarta Piñeiro-Núñez\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eChapter 21. Latanoprost (Xalatan), A Prostanoid FP Agonist for Glaucoma 329\u003cbr\u003e\u003ci\u003eSajiv K. Nair and Kevin E. Henegar\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003eIndex 339\u003c\/p\u003e \u003cp\u003e\u003ci\u003e\u003cb\u003eInnovative Drug Synthesis\u003c\/b\u003e\u003c\/i\u003e\u003c\/p\u003e \u003cp\u003ePreface xi\u003c\/p\u003e \u003cp\u003eContributors xiii\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART I. INFECTIOUS DISEASES 1\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eChapter 1. Entecavir (Baraclude): A Carbocyclic Nucleoside for the Treatment of Chronic Hepatitis B 3\u003c\/p\u003e \u003cp\u003eChapter 2. Telaprevir (Incivek) and Boceprevir (Victrelis): NS3\/4A Inhibitors for Treatment for Hepatitis C Virus (HCV) 15\u003c\/p\u003e \u003cp\u003eChapter 3. Daclatasvir (Daklinza): The First-in-Class HCV NS5A Replication Complex Inhibitor 43\u003c\/p\u003e \u003cp\u003eChapter 4. Sofosbuvir (Sovaldi): The First-in-Class HCV NS5B Nucleotide Polymerase Inhibitor 61\u003c\/p\u003e \u003cp\u003eChapter 5. Bedaquiline (Sirturo): A Diarylquinoline that Blocks Tuberculosis ATP Synthase for the Treatment of Multi-Drug Resistant Tuberculosis 81\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART II. CANCER 99\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eChapter 6. Enzalutamide (Xtandi): An Androgen Receptor Antagonist for Late-Stage Prostate Cancer 101\u003c\/p\u003e \u003cp\u003eChapter 7. Crizotinib (Xalkori): The First-in-Class ALK\/ROS Inhibitor for Non-small Cell Lung Cancer 119\u003c\/p\u003e \u003cp\u003eChapter 8. Ibrutinib (Imbruvica): The First-in-Class Btk Inhibitor for Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia 157\u003c\/p\u003e \u003cp\u003eChapter 9. Palbociclib (Ibrance): The First-in-Class CDK4\/6 Inhibitor for Breast Cancer 167\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART III. CARDIOVASCULAR DISEASES 197\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eChapter 10. Ticagrelor (Brilinta) and Dabigatran Etexilate (Pradaxa): P2Y12 Platelet Inhibitors as Anti-coagulants 199\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART IV. CNS DRUGS 223\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eChapter 11. Suvorexant (BELSOMRA): The First-in-Class Orexin Antagonist for Insomnia 225\u003c\/p\u003e \u003cp\u003eChapter 12. Lorcaserin (Belviq): Serotonin 2C Receptor Agonist for the Treatment of Obesity 243\u003c\/p\u003e \u003cp\u003eChapter 13. Fingolimod (Gilenya): The First Oral Treatment for Multiple Sclerosis 255\u003c\/p\u003e \u003cp\u003eChapter 14. Perampanel (Fycompa): AMPA Receptor Antagonist for the Treatment of Seizure 271\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART V. ANTI-INFLAMMATORY DRUGS 283\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eChapter 15. Tofacitinib (Xeljanz): The First-in-Class JAK Inhibitor for the Treatment of Rheumatoid Arthritis 285\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART VI. MISCELLANEOUS DRUGS 303\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003eChapter 16. Ivacaftor (Kalydeco): A CFTR Potentiator for the Treatment of Cystic Fibrosis 305\u003c\/p\u003e \u003cp\u003eChapter 17. Febuxostat (Uloric): A Xanthine Oxidase Inhibitor for the Treatment of Gout 317\u003c\/p\u003e \u003cp\u003eIndex 331\u003c\/p\u003e","brand":"John Wiley \u0026 Sons Inc","offers":[{"title":"Default Title","offer_id":53515638112599,"sku":"9781119185659","price":999.99,"currency_code":"GBP","in_stock":false}],"url":"https:\/\/bookcurl.com\/products\/drug-synthesis-book-set-9781119185659","provider":"Book Curl","version":"1.0","type":"link"}